『GLS Vitals Podcast Episode 10: Building the Future - Biotech Leadership & Global Impact』のカバーアート

GLS Vitals Podcast Episode 10: Building the Future - Biotech Leadership & Global Impact

GLS Vitals Podcast Episode 10: Building the Future - Biotech Leadership & Global Impact

無料で聴く

ポッドキャストの詳細を見る
WELCOME TO VITALS, THE PULSE OF GEORGIA LIFE SCIENCESDavid Dodd, CEO of Geovax, discussed the evolution of Georgia's life sciences ecosystem, emphasizing the persistence and collaboration of various stakeholders over decades. Geovax's focus is on developing the Geo MVA vaccine for monkeypox and smallpox, leveraging a platform with no contraindications. The company aims to establish advanced MVA manufacturing in Georgia, initially employing 25-50 people, expanding to 100+. Dodd highlighted the critical need for sustained investment in vaccine innovation and manufacturing to ensure global health security. He also stressed the importance of education and workforce development in fostering a robust life sciences ecosystem.David Dodd's Journey and Georgia's Life Sciences EcosystemMaria Thacker introduces David Dodd, CEO of Geovax, and highlights his long-standing involvement in Georgia's life sciences community.David Dodd reflects on the persistence and commitment of people in building Georgia's life sciences ecosystem over decades.David emphasizes the importance of resilience, capital scarcity, and long timelines in the biotech industry.Maria and David discuss the evolution of Georgia's life sciences hub, noting increased connectivity and awareness of Georgia's opportunities.David Dodd's Career Path and Personal JourneyDavid Dodd shares his career journey, starting in 1977 with Abbott Laboratories and progressing through various roles in big pharma, including Bristol Myers Squibb and Wyeth.David highlights his experience as CEO of Solvay Pharmaceuticals and his role in transforming the company's value from $100 million to $2.5 billion.David discusses his transition to NASDAQ companies and his involvement with Geovax, eventually becoming its CEO in 2018.David mentions his multiple attempts to retire and his current satisfaction with his work and the support of his wife.Geovax's Evolution and EnduranceDavid explains Geovax's evolution from a single-product HIV vaccine focus to a broader infectious disease vaccine platform.He highlights the relevance of Geovax's vaccine platform, which was used to eradicate smallpox and has been repurposed for other infectious diseases.David discusses the challenges of adapting to changing markets, funding environments, and public health priorities.He emphasizes the importance of disciplined prioritization, scientific credibility, and the ability to adapt in a challenging environment.Manufacturing Challenges and PreparednessDavid elaborates on the infrastructure-intensive nature of vaccine development and the unique challenges of manufacturing vaccines.He discusses the critical role of quality systems, regulatory alignment, and supply chain depth in vaccine manufacturing.David highlights the importance of sustained investment in preparedness between crises to avoid rebuilding capacity during emergencies.He provides examples of the impact of the monkeypox outbreak and the need for a global supply of vaccines.Geovax's Focus on Geo MVA and Clinical TrialsDavid outlines Geovax's current focus on Geo MVA, a vaccine candidate for monkeypox and smallpox preparedness.He explains the expedited regulatory path granted by the European Medicines Agency (EMA) for Geo MVA.David details the manufacturing process and the challenges of producing MVA vaccines quickly.He discusses the company's plans to establish advanced MVA manufacturing in Georgia and the support from state and federal legislators.Georgia's Role in Vaccine Innovation and BiosecurityDavid emphasizes the importance of Georgia's role in vaccine innovation and biosecurity.He highlights the state's potential to become a hub for vaccine innovation and biosecurity, leveraging its academic institutions and growing venture activity.David discusses the need for sustained investment in infrastructure and talent to support the life sciences ecosystem.He mentions the importance of collaboration and integration within the ecosystem to achieve long-term success.Leadership and Decision-Making in BiotechDavid shares his leadership philosophy, emphasizing the importance of execution, science, and talent development.He discusses the challenges of prioritizing multiple global health threats and the need for exquisite focus on critical programs.David highlights the importance of mentoring and staff development in building a strong team.He reflects on the evolution of Georgia's life sciences ecosystem and the role of policy makers and legislators in supporting the industry.Georgia's Life Sciences Ecosystem and Future ProspectsDavid expresses pride in the progress of Georgia's life sciences ecosystem and its potential to become a legitimate life sciences hub.He discusses the importance of long-term planning and investment in education and workforce development.David highlights the need for continued collaboration and support from the state and federal government to achieve the ecosystem's goals.He emphasizes the importance of maintaining ...
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません